Therapeutic efficacy of HER3-targeted nanobiologics on resistant tumors
Abstract
Elevated cell surface levels of the human epidermal growth factor receptor subunit 3 (HER3) are associated with resistance to a number of signal-blocking breast cancer treatments, including inhibitors of EGF-R (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy. Additionally, HER3 elevation has been identified on "untarget-able" tumors such as triple-negative breast cancer (TNBC), including TNBC with acquired resistance to EGF-R inhibition. Patients with such refractory tumors currently have limited treatment options and a poor prognosis. Moreover, as up to 70% of cases resist or acquire resistance to signal-blocking therapies, an alternative approach addressing this important clinical problem has the potential for significant clinical impact.
Additional Information
© 2016 American Association for Cancer Research.Additional details
- Eprint ID
- 67810
- Resolver ID
- CaltechAUTHORS:20160610-081611441
- Created
-
2016-06-10Created from EPrint's datestamp field
- Updated
-
2021-11-11Created from EPrint's last_modified field